deficit de hierro

¿Es usted
profesional sanitario?


Está usted accediendo a la página web “Déficit de Hierro”, dirigida a difundir información médica y promover la formación sobre los estados carenciales de hierro y la anemia ferropénica.

La información contenida en esta página está destinada exclusivamente a profesionales sanitarios con capacidad para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. Si Vd. no es profesional sanitario cualificado, Zambon no se hace responsable de los perjuicios que pueda sufrir por las decisiones basadas en el contenido de esta página o de cualquiera de sus enlaces.


Selección bibliográfica de artículos

Semestralmente se realiza una actualización de la revisión bibliográfica según los criterios establecidos.

La selección actual de artículos corresponde a material publicado desde enero de 2013 hasta febrero de 2017.

Los usuarios pueden solicitar a la Secretaría Científica el envío vía e-mail de aquellos artículos que sean de su interés.


  • Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.
    Okuturlar Y, Akalin N, Kaptanogullari OH, Guner NT, Yilmaz D, Gedikbasi A, Soyluk O, Mert M, Serin SO, Kocoglu H, Hursitoglu M, Kumbasar A.
    Ren Fail. 2016 Jun;38(5):781-6. doi: 10.3109/0886022X.2016.1162080. Epub 2016 Apr 6.

  • Diagnosis of Iron-Deficiency Anemia in Chronic Kidney Disease.
    Bahrainwala J, Berns JS.
    Semin Nephrol. 2016 Mar;36(2):94-8. doi: 10.1016/j.semnephrol.2016.02.002.

  • Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.
    Kalra PA, Bhandari S.
    Int J Nephrol Renovasc Dis. 2016 Mar 10;9:53-64. doi: 10.2147/IJNRD.S89704. eCollection 2016.

  • The Labile Side of Iron Supplementation in CKD.
    Slotki I, Cabantchik ZI.
    J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681

  • New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND, Kalantar-Zadeh K, Wish JB.
    Am J Kidney Dis. 2015 Nov 23. pii:S0272-6386(15)01322-0. doi: 10.1053/j.ajkd.2015.09.031.

  • Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study.
    Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF, Schwartz D, Silverberg DS, Chernin G.
    Cardiorenal Med. 2015 Oct;5(4):246-53

  • Is Intravenous Iron Supplementation Safe to Administer to Patients on Hemodialysis with Active Infection-What Do We Know, and What More Do We Need to Know?
    Bennett CL, Hermanson T.
    Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1714-5. doi: 10.2215/CJN.08060715

  • Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
    Bârsan L, Stanciu A, Stancu S, Căpuşă C, Brătescu L, Mandache E, Radu E, Mircescu G.
    Hematology. 2015 Oct;20(9):543-52. doi: 10.1179/1607845415Y.0000000004.

  • Oral or intravenous iron for anemia correction in chronic kidney disease?
    Drüeke TB, Massy ZA.
    Kidney Int. 2015 Oct;88(4):673-5. doi:10.1038/ki.2015.189. PubMed PMID: 26422625.

  • A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R, Kusek JW, Pappas MK.
    Kidney Int. 2015 Oct;88(4):905-14. doi:10.1038/ki.2015.163. Epub 2015 Jun 17.

  • How to Supplement Iron in Patients with Renal Anemia.
    Tanaka S, Tanaka T.
    Nephron. 2015;131(2):138-44. doi: 10.1159/000440773.

  • How the Target Hemoglobin of Renal Anemia Should Be.
    Mimura I, Tanaka T, Nangaku M.
    Nephron. 2015;131(3):202-9. doi: 10.1159/000440849. Epub 2015 Sep 19.

  • Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness.
    Yagil Y, Fadem SZ, Kant KS, Bhatt U, Sika M, Lewis JB, Negoi D.
    Ther Adv Chronic Dis. 2015 Sep;6(5):252-63. doi: 10.1177/2040622315589934. Review.

  • Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.
    Armaly Z, Abd El Qader A, Jabbour A, Hassan K, Ramadan R, Bowirrat A, Bisharat B.
    BMC Nephrol. 2015 Aug 13;16:135. doi: 10.1186/s12882-015-0119-0.

  • A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant. 2015 Aug 6. pii: gfv293.

  • Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
    Ribeiro S, Belo L, Reis F, Santos-Silva A.
    Blood Rev. 2015 Aug 18. pii: S0268-960X(15)00062-4. doi: 10.1016/j.blre.2015.07.006

  • The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study.
    Vikrant S, Parashar A.
    Indian J Nephrol. 2015 Jul-Aug;25(4):213-21. doi: 10.4103/0971-4065.144421.

  • Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis.
    Malkinska M, El Nekidy WS, El-Masri MM, Kadri A, Donaldson C, Soong D.
    Can J Hosp Pharm. 2015 Jul-Aug;68(4):304-10.

  • Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment.
    Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK, Kim JG.
    Diabetes Res Clin Pract. 2015 Jul;109(1):64-70. doi: 10.1016/j.diabres.2015.05.001

  • Considerations and challenges in defining optimal iron utilization in hemodialysis
    Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology
    J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922.

  • A randomized trial of intravenous and oral iron in chronic kidney disease
    Rajiv Agarwal, John W Kusek and Maria K Pappas
    Kidney Int. doi:10.1038/ki.2015.163

  • Dysregulated iron metabolism in patients on hemodialysis.
    Nakanishi T, Hasuike Y, Otaki Y, Nanami M, Kuragano T.
    Contrib Nephrol. 2015;185:22-31. doi: 10.1159/000380967

  • Renal functional and structural integrity in infants with iron deficiency anemia: relation to oxidative stress and response to iron therapy.
    El-Shimi MS, El-Farrash RA, Ismail EA, El-Safty A, Nada AS, El-Gamel OA, Salem YM, Shoukry SM.
    Pediatr Nephrol.

  • Heme iron polypeptide for the management of anaemia of chronic kidney disease.
    Dull RB, Davis E
    J Clin Pharm Ther. 2015 Aug;40(4):386-90. doi: 10.1111/jcpt.12281.

  • Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
    Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B.
    Nephrol Dial Transplant. 2015 Apr;30(4):645-52. doi: 10.1093/ndt/gfu357.

  • Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
    Negri AL, Ureña Torres PA
    Clin Kidney J. 2015 Apr;8(2):161-7. doi: 10.1093/ckj/sfu139

  • Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis
    Kuo KL, Hung SC, Liu JS, Chang YK, Hsu CC, Tarng C.
    Nephrol Dial Transplant. DOI: doi: 10.1093/ndt/gfv085

  • Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial.
    Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M, Pisani A.
    PLoS One. 2015 Mar 17;10(3):e0118174. doi: 10.1371/journal.pone.0118174. eCollection 2015.

  • Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
    Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S.
    Saudi J Kidney Dis Transpl. 2015 Jan;26(1):19-25.

  • Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
    Toblli JE, Di Gennaro F, Rivas C.
    Heart Lung Circ. 2015 Jan 21. pii: S1443-9506(15)00034-7. doi: 10.1016/j.hlc.2014.12.161. [Epub ahead of print].

  • C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
    Martínez-Castelao A, Cases A, Coll E, Bonal J, Galceran JM, Fort J, Moreso F, Torregrosa V, Guirado L, Ruiz P; Investigators of the Micenas II study.
    Nefrologia. 2015;35(1):80-6. doi: 10.3265/Nefrologia.pre2014.Sep.12588. Epub 2014 Oct 22.

  • Iron supplementation and mortality in incident dialysis patients: an observational study.
    Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, Weiss G.
    PLoS One. 2014 Dec 2;9(12):e114144

  • Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.
    Takasawa K, Takaeda C, Maeda T, Ueda N.
    Nutrients. 2014 Dec 29;7(1):103-18. doi: 10.3390/nu7010103.

  • Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.
    Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Ebony Boulware L; for The DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.
    Nephrol Dial Transplant. 2014 Nov 2. pii: gfu349. [Epub ahead of print]

  • Intravenous iron exposure and mortality in patients on hemodialysis.
    Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators.
    Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1930-9.

  • Malondialdehyde, antioxidant enzymes, and renal tubular functions in children with iron deficiency or iron-deficiency anemia.
    Altun D, Kurekci AE, Gursel O, Hacihamdioglu DO, Kurt I, Aydin A, Ozcan O.
    Biol Trace Elem Res. 2014 Oct;161(1):48-56. doi: 10.1007/s12011-014-0084-7. Epub 2014 Aug 8.

  • Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease.
    Hazara AM, Bhandari S.
    J Clin Pharm Ther. 2014 Oct 10.

  • Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
    Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T.
    Kidney Int. 2014 Oct;86(4):845-54.

  • Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia.
    Rostoker G, Cohen Y.
    J Comput Assist Tomogr. 2014 Sep 16. [Epub ahead of print]

  • Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.
    Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA.
    BMC Nephrol. 2014 Sep 22; 15:154

  • Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
    Dossabhoy NR, Turley S, Gascoyne R, Tapolyai M, Sulaiman K.
    Ren Fail. 2014 Aug;36(7):1033-7. doi: 10.3109/0886022X.2014.918785. Epub 2014 May 21.

  • Cumulative iron dose and resistance to erythropoietin.
    Rosati A, Tetta C, Merello JI, Palomares I, Pérez-García R, Maduell F, Canaud B, Aljama García P.
    J Nephrol. 2014 Aug 5. [Epub ahead of print]

  • The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study.
    Aydin Z, Gursu M, Karadag S, Uzun S, Sumnu A, Doventas Y, Ozturk S, Kazancioglu R.
    Ren Fail. 2014 Jul 21:1-5. [Epub ahead of print]

  • Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.
    Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.
    Kidney Int. 2014 Jul 30. doi: 10.1038/ki.2014.275. [Epub ahead of print]

  • FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC, et al.
    Nephrol Dial Transplant. 2014 Jun 2. pii: gfu201 [Epub ahead of print]

  • The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease.
    Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; the NephroTest Study Group.
    PLoS One. 2014 Jun 30;9(6):e99781. doi: 10.1371/journal.pone.0099781. eCollection 2014.

  • Iron Metabolism in Transplantation.
    Schaefer B, Effenberger M, Zoller H.
    Transpl Int. 2014 Jun 25. doi: 10.1111/tri.12374. [Epub ahead of print]

  • New treatment approaches in chronic kidney disease-associated anaemia.
    Del Vecchio L, Locatelli F.
    Expert Opin Biol Ther. 2014 May;14(5):687-96. doi: 10.1517/14712598.2014.892577. Epub 2014 Mar 1.

  • Anemia in Chronic Kidney Disease Treating the Numbers, Not the Patients.
    Coyne DW.
    JAMA Intern Med. 2014 May;174(5):708-9.

  • Iron dosing in kidney disease: inconsistency of evidence and clinical practice.
    Gaweda AE, et al.
    Neprhol Dial Transplant, 2014; May.

  • Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
    Brätescu LO, et al.
    Int Urol Nephrol, 2014; May: 46 (5): 1005-1012.

  • Hepcidin levels in chronic hemodialysis patients: a critical evaluation.
    Valenti L, et al.
    Clin Chem Lab Med, 2014; 52 (5): 613-619.

  • Distinct immunologic effects of different intravenous iron preparations on monocytes.
    Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH.
    Nephrol Dial Transplant. 2014 Apr;29(4):809-22. doi: 10.1093/ndt/gft524. Epub 2014 Feb 11.

  • The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W.
    Nephrol Dial Transplant. 2014 Apr 19. [Epub ahead of print]

  • Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol. 2014 Apr 2. [Epub ahead of print]

  • Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.
    Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R.
    J Nephrol. 2014 Apr 1. [Epub ahead of print]

  • Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients.
    Takasawa K, et al.
    Nephron Extra, 2014; 4 (1): 55-63.

  • A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC, et al.
    Clin J Am Soc Neprhol, 2014; 9 (4): 705-712.

  • Prevalencia de anemia y su manejo clínico en la enfermedad renal crónica estadios 3-5 no en diálisis en Cataluña: estudio MICENAS I.
    Cases-Amenós A, Martínez-Castelao A, Fort-Ros J, Bonal-Bastons J, Ruiz MP, Vallés-Prats M, Coll-Piera E, Galcerán-Gui JM.
    Nefrologia 2014;34(2):189-198 | Doi. 10.3265/Nefrologia.pre2013.Dec.12261.

  • The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences.
    Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P.
    Eur J Heart Fail. 2014 Mar 18. doi: 10.1002/ejhf.84. [Epub ahead of print]

  • Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States (1995-2010).
    Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM.
    JAMA Intern Med. 2014 Mar 3. doi: 10.1001/jamainternmed.2014.87. [Epub ahead of print]

  • The pathophysiology and pharmacology of hepcidin.
    Ruchala P, Nemeth E.
    Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/ Epub 2014 Feb 17.

  • The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.
    Zumbrennen-Bullough K, Babitt JL.
    Nephrol Dial Transplant. 2014 Feb;29(2):263-73.

  • Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P, et al.
    Am J Nephrol. 2014;39(2):130-41. doi: 10.1159/000358336. Epub 2014 Feb 7.

  • A 3-marker index improves the identification of iron disorders in CKD anaemia.
    Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Gauci C, Froissart M, Stengel B; NephroTest Study Group.
    PLoS One. 2014 Feb 19;9(2):e84144. doi: 10.1371/journal.pone.0084144. eCollection 2014.

  • Pathophysiology of anemia in chronic kidney diseases. A review.
    Zadrazil J, Horak P.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Jan 3. doi: 10.5507/bp.2013.093.

  • Prevalence of anemia in chronic kidney disease in the United States.
    Stauffer ME, Fan T.
    PLoS One. 2014 Jan 2;9(1):e84943. doi: 10.1371/journal.pone.0084943.

  • Iron and infection in hemodialysis patients.
    Ishida JH, Johansen KL.
    Semin Dial. 2014 Jan;27(1):26-36. doi: 10.1111/sdi.12168.

  • Update on intravenous iron choices.
    Larson DS, Coyne DW.
    Curr Opin Nephrol Hypertens. 2014 Jan 7.

  • TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.
    Gaweda AE, Bhat P, Maglinte GA, Chang CL, Hill J, Park GS, Ashfaq A, Gitlin M.
    Hemodial Int. 2014 Jan;18(1):38-46. doi: 10.1111/hdi.12078.

  • Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S.
    Kidney Int. 2014 Jan 8. doi: 10.1038/ki.2013.528.

  • Severe hypophosphataemia after intravenous iron administration.
    Blazevic A, Hunze J, Boots JM.
    Neth J Med. 2014 Jan;72(1):49-53.

  • Trends in anemia management in US hemodialysis patients 2004-2010.
    Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.
    BMC Nephrol. 2013 Dec 1;14:264. doi: 10.1186/1471-2369-14-264.

  • New renal anemia drugs: is there really anything new on the horizon?
    Malyszko J.
    Expert Opin Emerg Drugs. 2013 Dec 18.

  • Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
    Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, Mangione F, Esposito P, Dal Canton A; REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group.
    Nephrol Dial Transplant. 2013 Dec;28(12):3035-45.

  • Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.
    Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA.
    PLoS One. 2013 Nov 1;8(11):e78930. doi: 10.1371/journal.pone.0078930. eCollection 2013.

  • Low hepcidin triggers hepatic iron accumulation in patients with hepatitis.
    Hörl WH, Schmidt A.
    Nephrol Dial Transplant. 2013 Nov 27.

  • Blood disorders after kidney transplantation.
    Reindl-Schwaighofer R, Oberbauer R.
    Transplant Rev (Orlando).2013 Oct 10. pii: S0955-470X(13)00108-0. doi: 10.1016/j.trre.2013.10.001.

  • Iron toxicity: relevance for dialysis patients.
    Fishbane S, Mathew A, Vaziri ND.
    Nephrol Dial Transplant.2013 Oct 28.

  • Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.
    Nephrol Dial Transplant. 2013 Oct;28(10):2570-9.

  • Iron deficiency anaemia in chronic kidney disease.
    Wittwer I.
    J Ren Care.2013 Sep;39(3):182-8. doi: 10.1111/j.1755-6686.2013.12026.x.

  • Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.
    Nephrol Dial Transplant. 2013 Aug 20.

  • Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.
    Vaziri ND.
    Am J Kidney Dis.2013 Jun;61(6):992-1000. doi: 10.1053/j.ajkd.2012.10.027.

  • Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.
    Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV.
    J Am Soc Nephrol. 2013 Jun;24(7):1151.

  • Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
    Goldstein SL, Morris D, Warady BA.
    Am J Kidney Dis.2013 Apr;61(4):588-97. doi: 10.1053/j.ajkd.2012.10.019.

  • Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
    Nephrol Dial Transplant.2013 Apr;28(4):953-64. doi: 10.1093/ndt/gfs528.

  • Greater potency of darbepoetin-α; than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S, Inaba M, Tomosugi N, Okuno S, Ichii M, Yamakawa T, Kurihara S.
    Eur J Haematol. 2013 Mar;90(3):237-44. doi: 10.1111/ejh.12067.

  • An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
    Wong G, Howard K, Hodson E, Irving M, Craig JC.
    Nephrol Dial Transplant.2013 Feb;28(2):413-20. doi: 10.1093/ndt/gfs487.

  • Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 83 [Internet].
    Chung M, Chan JA, Moorthy D, Hadar N, Ratichek SJ, Concannon TW, Lau J.
    Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jan. Report No.: 13-EHC038-EF. AHRQ Comparative Effectiveness Reviews.

  • Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC, Geisser P.
    Iran J Kidney Dis.2013 Jan;7(1):9-22.

Deje su comentario:
Entre en su área de usuario para comentar.
No hay comentarios.